The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Advances in immunotherapy for multiple myeloma
Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, discusses developments in the field of immunotherapy for multiple myeloma. There are currently a lot of efforts to improve the persistence of CAR-Ts, as well as to improve the speed of CAR-T therapy manufacturing, and to develop allogeneic CAR-T products. In parallel, bispecific antibodies targeting different antigens and natural killer (NK) cell therapies are also being developed. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
